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High glucose activates HIF-1-mediated signal
transduction in glomerular mesangial cells through
a carbohydrate response element binding protein
Tsubasa Isoe1, Yuichi Makino1, Katsutoshi Mizumoto1, Hidemitsu Sakagami1, Yukihiro Fujita1, Jun Honjo1,
Yumi Takiyama1, Hiroshi Itoh1 and Masakazu Haneda1
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High glucose evokes a variety of signals in mesangial cells
that alter cellular functions responsible for the development
of diabetic glomerulopathy. The hypoxia-inducible factor-1a
(HIF-1a) regulates cellular homeostasis under hypoxic
conditions, but it also has pleiotropic effects in response to
cellular stresses at normoxia. Here we determined whether
HIF-1a has a role in the regulation of mesangial cells in
hyperglycemia. In the streptozotocin-induced diabetic mouse
model, glomerular mesangial cells had a significant increase
in HIF-1a expression in the nucleus. In cultured mesangial
cells, high glucose enhanced the expression of HIF-1a and its
target genes known to be involved in the development of
diabetic glomerulopathy. A glucose-responsive carbohydrate
response element binding protein (ChREBP) was found to
have a critical role in the transcriptional upregulation of
HIF-1a and downstream gene expression in mesangial cells
exposed to high glucose. Knockdown of HIF-1a or ChREBP in
mesangial cells abrogated the high glucose-mediated
perturbation of gene expression. Our results show that
ChREBP and HIF-1a mediate gene regulation in mesangial
cells. Further studies will be needed to find out whether
these findings are relevant to the development of the
diabetic nephropathy.
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Diabetic nephropathy is the leading cause of end-stage renal
disease worldwide and a high risk for the development of
cardiovascular disease.1,2 Clinical studies, such as the
Diabetes Control and Complications Trial in patients with
type I diabetes3 and UK Prospective Diabetes Study in
patients with type II diabetes,4 show a linkage between
sustained hyperglycemia and the occurrence of vascular
complications of diabetes, including nephropathy. Moreover,
maintenance of normoglycemia by pancreatic transplantation
in patients with type I diabetes resulted in amendment of
glomerular pathologic features.5 Therefore, elucidation of the
hyperglycemia-related molecular pathogenesis of organ
damage would provide further insight into the therapeutic
strategies for diabetic nephropathy.
A histological hallmark of diabetic nephropathy is an
excessive accumulation of extracellular matrix proteins in the
glomeruli.6 Multiple mechanisms, including hyperglycemia-
induced metabolic and hemodynamic changes7 and genetic
predisposition,8 have been shown to induce functional
changes in glomerular mesangial cells. High glucose
ambience induces increased glycolytic flux of polyols9 and
hexosamines,10 formation of advanced glycation end
products11 and reactive oxygen species,12 activation of
protein kinase C,13 and production of cytokines such as
transforming growth factor-b1 and connective tissue growth
factor (CTGF),14 all of which cause overproduction of matrix
proteins by mesangial cells.15 High glucose also induces
inhibitors of matrix-degrading enzymes including plasmino-
gen activator inhibitor-1 (PAI-1), which also leads to an
accumulation of extracellular matrix proteins.16 The precise
mechanism of gene regulation by high glucose underlying
such mesangial dysfunctions, however, remains to be
explored.
The hypoxia-inducible factor (HIF)-1 is a heterodimeric
transcription factor composed of HIF-1a and HIF-1b
subunits.17 Upon cellular exposure to hypoxic conditions,
HIF-1 is activated to induce transcription of genes encoding
erythropoietin,18 vascular endothelial growth factor19 and
CTGF,20 glycolytic enzymes,21 glucose transporters,22 and
PAI-1.23 The mechanism for regulation of HIF-1 by oxygen
has been determined.24 Under normoxic conditions, HIF-1a
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is targeted by the von Hippel-Lindau protein for ubiquityla-
tion and rapid proteasomal degradation. Binding of von
Hippel-Lindau protein is mediated through hydroxylation of
specific prolyl residues in HIF-1a protein catalyzed by HIF
prolyl hydroxylases. Hypoxia decreases the prolyl hydroxyla-
tion, resulting in release of von Hippel-Lindau protein and
stabilization of HIF-1a protein.25 Stabilized HIF-1a translo-
cates to the nucleus in which it dimerizes with HIF-1b to
bind to the hypoxia-response element of target genes, and
thereafter recruits cofactors such as CBP/P300 to elicit
transactivation of the target genes.26
In addition to the activation by hypoxia, evidence suggests
that various cellular stimuli activate HIF-1a even under
normoxic conditions. For example, transforming growth
factor-b127 and angiotensin II,28 metabolites in citric acid
cycle, including fumarate,29 reactive oxygen species,30 and
protein kinase C,31 activate HIF-1a. Therefore, it is plausible
that HIF-1 has critical roles in regulation of cellular functions
not only under hypoxic conditions, but also in conditions
such as metabolic disturbance and inflammation. In addi-
tion, a fraction of HIF-1 target genes is superimposed on the
genes dysregulated in the diabetic kidney, indicating a
contribution of HIF-1 to the development of diabetic
glomerulopathy. Along this issue, a recent study has
suggested an enhanced expression of HIF-1a in the glomeruli
of diabetic mice, although the underlying mechanism and
functional relevance of the induction remained to be
elucidated.32 The present study examined the effect of
hyperglycemic ambience on the expression and functions of
HIF-1 in mesangial cells and showed a critical involvement of
glucose-responsive transcriptional mechanisms to confer
HIF-1a a role in the functional derangement of glomerular
mesangial cells in diabetic circumstances.
RESULTS
HIF-1a is expressed in glomerular mesangial cells of diabetic
model mouse
We first examined the expression of HIF-1a in the glomeruli
of diabetic model mice using immunohistochemical methods.
Kidneys from the diabetic or non-diabetic mice at 24 weeks
after streptozotocin or vehicle injection were tested for HIF-
1a staining. At this stage, a modest mesangial expansion was
detected in the diabetic mice (Figure 1a). Notably, in the
glomeruli of diabetic kidney, HIF-1a-positive cells were
found with significantly higher incidence compared with the
control mice (Figure 1a and b). The ratio of the numbers of
HIF-1a-positive cells to that of total glomerular cells was also
significantly increased in diabetic mice (Figure 1b); therefore,
cellular hyperplasia does not explain the increase in the
number of HIF-1a-positive cells. Another diabetic model of
db/db mice similarly showed a significant increase of HIF-1a-
positive cells in the glomeruli compared with control m/db
mice (Figure 1c and d). To characterize the cells expressing
HIF-1a in the glomeruli, we performed co-immunofluor-
escent staining. The cells with positive staining for HIF-1a
or a-smooth muscle actinin, which is often induced in
mesangial cells in injured glomeruli,33 were increased in
streptozotocin-induced diabetic mice. A major part of HIF-
1a-positive cells coincided with a-smooth muscle actinin and
40,6-diamidino-2-phenylindole signals (Figure 2a, arrows),
indicating an increase of HIF-1a in the nucleus of mesangial
cells in diabetic kidneys. Co-staining of HIF-1a and Wilms’
tumor-1, a marker of podocytes,34 depicted only a few
overlaps of HIF-1a and Wilms’ tumor-1 signals and those
HIF-1a/Wilms’ tumor-1 co-positive cells hardly merged with
40,6-diamidino-2-phenylindole signals (Figure 2b). The co-
staining with CD34, a marker of vascular endothelial cells,35
failed to show the presence of induced HIF-1a in endothelial
cells in the glomeruli (Figure 2c). Semiquantitative summary
of these co-immunofluorescent studies revealed that HIF-1a
is most abundantly expressed in the nucleus of the mesangial
cells in the diabetic glomeruli (Figure 2d), suggesting a
productive role of HIF-1a in mesangial cells under diabetic
conditions.
High glucose induces expression of HIF-1a in mesangial cells
Given the in vivo results, we focused on mesangial cells to
determine the effect of glucose on the expression of HIF-1a.
Primary human mesangial cells maintained in the medium
with normal level of glucose (5.6mmol/l D-glucose) under
normoxic (21% O2) conditions showed a weak basal HIF-1a
expression, and the cellular exposure to hypoxia (1% O2)
induced higher expression of HIF-1a (Figure 3a and b).
Similarly, in human renal proximal tubular epithelial cells and
in HeLa cells, HIF-1a was scarcely detected under normoxic
conditions but was dramatically elevated by hypoxia (Figure 3a
and b). Interestingly, high glucose (25mmol/l D-glucose) medium
induces a significantly higher level of HIF-1a protein in
human mesangial cells even under normoxic conditions and
further induction was observed under hypoxic conditions
(Figure 3a and b). The induction of HIF-1a by glucose under
normoxic condition was concentration dependent; the effect
was visible at 11mmol/l and became evident above 17mmol/l
(Figure 3c). Moreover, osmolarity-controlled medium failed
to enhance the HIF-1a expression (Figure 3d), indicating that
glucose is potentially responsible for the upregulation of
HIF-1a. On the other hand, tubular epithelial cells and HeLa
cells did not respond to high glucose medium (Figure 3a
and b), indicating that upregulation of HIF-1a by high
glucose might be a cell type-preferential effect. In support of
this, in mouse mesangial cells, HIF-1a was induced by high
glucose medium under normoxic conditions, whereas in mouse
renal tubular epithelial cells such response was absent (Figure 3e).
Taken together, high glucose upregulates HIF-1a expression
irrespective of oxygen concentration in certain types of cells,
for example, mesangial cells.
High glucose induces hypoxia-inducible genes even under
normoxic conditions through HIF-1a in mesangial cells
To explore the role of HIF-1a induced by high glucose in
mesangial cells under normoxic condition, transcriptional
competence of HIF-1a was evaluated. Mouse mesangial cells
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were transiently transfected with a hypoxia-responsive
luciferase reporter and cultured in different concentrations
of glucose under either normoxic or hypoxic conditions.
Hypoxic culture caused strong luciferase expression in either
normal or high glucose medium (Figure 4a). High glucose
culture under normoxic conditions, although not as strong as
hypoxia, significantly activated reporter gene (Figure 4a),
indicating that high glucose induces transcriptionally active
HIF-1. Consistently, mRNAs of HIF-1 target genes, including
CTGF, PAI-1, hexokinase II, glucose transporter-1, vascular
endothelial growth factor, and adrenomedullin, which have
been implicated in the pathology of diabetic kidney,15,16,36
were significantly upregulated by high glucose even under
normoxic conditions in both human or mouse mesangial
cells (Figure 4b and c). High glucose induced glucose
transporter-1 expression comparably to hypoxic conditions,
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Figure 1 |Hypoxia-inducible factor-1a (HIF-1a) is expressed in the glomeruli of diabetic model mouse. (a, b) Streptozotocin
(STZ)-induced diabetic and control mice were dissected at 24 weeks after treatment, and immunohistochemical analyses for HIF-1a
expression in the glomeruli were performed. (a, upper panel) Representative photomicrographs of periodic acid Schiff (PAS)-stained kidney
sections and (a, bottom panel) immunohistochemical staining of HIF-1a are shown (original magnification  800). Bars¼ 25mm.
Semiquantitative analyses for HIF-1a-positive cells were performed as indicated in Materials and Methods. Five independent analyses were
performed, and (b, upper graph) the mean±s.d. of the number of the positive cells per glomerulus and (b, bottom graph) the ratio of
positive cells to the total number of the counted cells are indicated. (c, d) The expression of HIF-1a in the glomeruli of 18-week-old diabetic
db/db mice and non-diabetic m/db mice. (c, upper panel) PAS staining and (c, bottom panel) immunohistochemical staining of HIF-1a are
shown (original magnification  800). Bars¼ 25 mm. (d, upper graph) HIF-1a-positive cells per glomeruli and (d, bottom graph) the ratio of
positive cells to the total number of the cells are determined. **Po0.01 versus the control or m/db mouse.
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Figure 2 |Hypoxia-inducible factor-1a (HIF-1a) is expressed in the nucleus of mesangial cells in the glomeruli of diabetic model
mouse. (a–c) Immunofluorescent study for HIF-1a and a-smooth muscle actinin (a; a-SMA), Wilms’ tumor-1 (b; WT-1), and CD34 (c; CD34)
expression in the glomeruli of streptozotocin (STZ)-induced diabetic mice. Bars¼ 25 mm. (d) Semiquantitative analyses of the cells
co-positive for HIF-1a and for each marker were performed by the counting of 25 glomeruli to determine the ratio of co-positive cells to
the total number of the counted cells. Nuclear localization of HIF-1a was diagnosed by mergence of HIF-1a signals with 40,6-diamidino-
2-phenylindole (DAPI) signals that were otherwise diagnosed as cytoplasmic. **Po0.01.
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whereas the induction of adrenomedullin by high glucose was
weaker than that by hypoxia (Figure 4d). This indicates that
transcriptional activity of the glucose-induced HIF-1a might
be diverse in the context of promoter structures. To further
clarify the involvement of HIF-1a in high glucose-mediated
gene regulation, the small interfering RNA (siRNA) targeting
HIF-1a was introduced into mouse mesangial cells to
downregulate HIF-1a in either normal or high glucose
medium (Figure 4e). This knockdown of HIF-1a in the
cells diminished the high glucose-dependent induction of
genes such as CTGF and PAI-1 (Figure 4f) under normoxic
conditions. Therefore, HIF-1a induced by high glucose has a
role in the perturbation of the gene expression profile in the
mesangial cells exposed to high glucose.
High glucose induces HIF-1a mRNA expression
To determine the mechanism underlying high glucose-
mediated upregulation of HIF-1a in mesangial cells, the
effect of the protein synthesis inhibition on the HIF-1a
protein behavior was assessed. 2,20-dipyridyl is a hypoxia-
mimicking chemical to stabilize HIF-1a proteins.37 As shown
in Figure 5a, 2,20-dipyridyl caused massive accumulation of
HIF-1a protein in mouse mesangial cells. Addition of a
protein synthesis inhibitor, cycloheximide, did not alter the
level of HIF-1a stabilized by 2,20-dipyridyl. In contrast,
HIF-1a induced by high glucose was prone to cycloheximide
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Figure 4 |High glucose induces hypoxia-inducible genes even under normoxic conditions through hypoxia-inducible factor-1a
(HIF-1a) in the mesangial cells. (a) Mouse mesangial cells (mMC) were transiently transfected with hypoxia response element-driven
firefly luciferase reporter and control Renilla luciferase expression plasmids and then cultured in normal glucose (NG, 5.6mmol/l D-glucose)
or high glucose (HG, 25mmol/l D-glucose) medium for 24 h under normoxic (21% O2) conditions , and finally exposed to hypoxic conditions
(1% O2) for 24 h. Firefly luciferase activity was normalized by Renilla luciferase activity. The means±s.d. of firefly luciferase activity relative
to cells in NG medium under normoxic conditions are presented. *Po0.05 and **Po0.01 in comparison to the cells in NG medium under
normoxic conditions. (b, c) Human mesangial cells (b; hMC) and mMC (c) were incubated for 48 h in NG or HG medium and mRNA
expression of the indicated genes was determined by real-time PCR as indicated in Materials and Methods. ADM, adrenomedullin;
CTGF, connective tissue growth factor; GLUT-1, glucose transporter-1; HKII, hexokinase II; PAI-1, plasminogen activator inhibitor-1;
VEGF, vascular endothelial growth factor. The means±s.d. of mRNA levels relative to cells in NG medium are presented. *Po0.05 and
**Po0.01 in comparison to the cells in NG medium. (d) mMC were incubated for 24 h in NG or HG medium and then cultured under either
normoxic or hypoxic conditions for 24 h. GLUT-1 and ADM mRNA levels were determined by real-time PCR. The means±s.d. of mRNA levels
relative to cells in NG medium under normoxic conditions are presented. *Po0.05 and **Po0.01 in comparison to the cells in NG medium
under normoxic conditions. (e) Small interfering RNA (siRNA) targeting HIF-1a (þ ) was introduced to mMC, and then the cells were
incubated in NG or HG medium for 48 h. A non-target siRNA was used as a control (). HIF-1a expression under hypoxic conditions
was determined by immunoblot. (f) CTGF and PAI-1 mRNA levels in the cells transfected with HIF-1a siRNA (þ ) or with control scrambled
non-targeting siRNA() were examined by real-time PCR. mRNA levels relative to control siRNA-transfected cells under NG condition
are presented as the mean values±s.d. of four independent experiments. **Po0.01, wwPo0.01.
Figure 3 |High glucose induces expression of hypoxia-
inducible factor-1a (HIF-1a) in glomerular mesangial cells.
(a, b) Human mesangial cells (hMC), human renal proximal
tubular epithelial cells (hRPTEC), and HeLa cells were incubated
in normal glucose medium (NG; 5.6mmol/l D-glucose) or high
glucose medium (HG; 25mmol/l D-glucose) as indicated in Materials
and Methods, and thereafter exposed to either normoxic (21% O2)
or hypoxic (1% O2) conditions for 6 h. (a) Immunoblot analyses for
expression of HIF-1a and (b) the mean±s.d. of the relative
expression level of HIF-1a to a-actinin level from five independent
experiments are presented. *Po0.05 and **Po0.01 in comparison
to NG under 21% O2.
wPo0.05; wwPo0.01. (c) hMC were incubated
in the medium containing the indicated concentrations of glucose
for 48 h and HIF-1a expression was then determined by
immunoblot. (d) hMC were incubated in NG, HG, or osmolarity-
equivalent medium (NGO; 5.6mmol/l D-glucose and 19.4mmol/l
L-glucose) for 48 h. The means±s.d. of densitometric values of
HIF-1a expression relative to b-actin from five independent
experiments are shown. *Po0.01 in comparison to the cells in NG.
(e) Mouse MC (mMC) or RPTEC (mRPTEC) were incubated for 48 h
in NG or HG medium under normoxic conditions. The
representative immunoblots are shown.
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treatment to be rapidly decreased to the basal level (Figure
5b), indicating that high glucose enhances HIF-1a expression
through a mechanism distinct from protein stabilization.
Although the expression of HIF-prolyl hydroxylases 3 is
induced under hypoxic conditions,38 its availability and
activity for hydroxylation of HIF-1a are shown to be down-
regulated by hypoxia to liberalize HIF-1a from degradation
pathways.39 High glucose did not alter HIF-prolyl hydro-
xylases 3 levels in mesangial cells (Figure 5c), suggesting that
an escape from the degradation is not a likely explanation for
high glucose-mediated accumulation of HIF-1a. On the
other hand, mRNA level of HIF-1a was increased by high
glucose in both human and mouse mesangial cells. Interest-
ingly, as in the protein analysis, HIF-1amRNA induction was
absent in human renal tubular epithelial cells (Figure 5d).
Moreover, in situ hybridization analysis showed stronger
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expression of HIF-1a mRNA in the glomeruli of streptozo-
tocin-induced diabetic mice than in control mice (Figure 5e).
Taken together, glucose-dependent transcriptional regulation
might be involved in HIF-1a induction in the mesangial cells
by diabetic ambience.
ChREBP has a role in HIF-1a mRNA induction by high glucose
Sequence analyses showed that the promoters of HIF-1a
genes are highly conserved between humans and mice.40
There are three conserved E-box-like sequences in the HIF-1a
gene promoters. The proximal E-box-like sequences at 254
and 243 bp from the transcriptional start sites are separated
by 5-nucleotide spacer and thus potentially constitute the
carbohydrate response element (ChRE), an element known to
respond to glucose (Figure 6a).41 Given this fact, the
truncated fragments of the 50-flanking region of HIF-1a
gene were cloned into a luciferase vector (Figure 6b), and
mouse mesangial cells were transiently transfected with the
reporter plasmids and cultured in either normal or high
glucose medium for luciferase assays. Cells transfected with
either PGL3-basic plasmid or pHIF-1a/-233 reporter did not
show luciferase induction in response to high glucose (Figure
6c). In contrast, the reporters carrying the 326 and 611 bp
long segments of the promoter, pHIF-1a/-326 and pHIF-1a/-
611, both containing the ChRE-like sequence, showed
induction response to high glucose (Figure 6c). Moreover,
nucleotide substitutions in the cores of each E-box-like
sequence (CAGCTG to CTTAAG) in the pHIF-1a/-611
reporter, generating pHIF-1a/-611 M1 and M2 constructs
(Figure 6d), abolished induction response to high glucose
(Figure 6e). Taken together, the ChRE-like sequence is
critically involved in HIF-1a mRNA upregulation by high
glucose.
ChREBP is a transcription factor binding to the ChRE and
has a pivotal role in the glycolytic and lipogenic gene
regulation in, for example, liver and adipose tissues,41
whereas the role of ChREBP in the kidney remains unknown.
To analyze the effect of ChREBP on the regulation of HIF-1a
gene in mesangial cells, we carried out chromatin immuno-
precipitation assays. Anti-ChREBP antibodies efficiently
precipitated the DNA fragments containing ChRE-like
sequence in HIF-1a promoter from human mesangial cells
treated with high glucose (Figure 6f), indicating the binding
of ChREBP to the HIF-1a promoter in mesangial cells
exposed to high glucose. Moreover, the siRNA-mediated
reduction of cellular ChREBP level resulted in an elimination
of HIF-1a mRNA response to high glucose (Figure 6g). On
the other hand, the ChRE was also found in the putative
promoter region of the HIF-2a gene (data not shown). In
support of this, HIF-2a expression was upregulated by high
glucose in mesangial cells but not in renal tubular epithelial
cells (Figure 6h). Notably, protein level of ChREBP in the
nucleus of mesangial cells dominated over that of the tubular
epithelial cells, which might correlate with the cell-type
specificity for HIF-1a or HIF-2a induction by high glucose
(Figure 6i). Moreover, knockdown of ChREBP resulted in
abrogation of high glucose-mediated induction of HIF-1
target genes including CTGF and PAI-1 (Figure 6j),
indicating a critical contribution of ChREBP in HIF-1-
mediated gene regulation in mesangial cells. In conclusion,
HIF-1a (and maybe HIF-2a also) disposes ChREBP as a
glucose sensor for regulation of its expression to participate
in gene regulation in the mesangial cells in response to
high glucose.
DISCUSSION
Recent studies have shown that HIF-1 is involved in the
pathogenesis of a variety of kidney diseases. For example, a
high level of HIF-1a is found in the tubulo-interstitial region,
possibly due to the local hypoxia in an acute renal failure
model.42 Interstitial ischemia constitutes a final common
pathway to the end-stage kidney diseases in which HIF-1a
may operate a cellular protective mechanism.43 On the other
hand, the activation of HIF-1a in podocytes is suggested to
be associated with the cellular survival disadvantage and the
formation of glomerular crescents in rapidly progressive
glomerulonephritis.44 In the present study, we showed an
increased expression of HIF-1a in the glomeruli of two
different diabetic model mice. Streptozotocin-induced dia-
betes represents a model of human type I diabetes,45 and db/
db mice46 resemble type II diabetes; thus, the augmentation
of the HIF-1a expression in diabetic glomeruli seems to be
irrespective of the etiology of diabetes. Co-immunofluor-
escent analyses indicated that mesangial cell is a major site of
HIF-1a expression in the glomeruli in diabetes. As most part
of HIF-1a was accumulated in the nucleus of mesangial cells,
the expression of HIF-1a might comprise an epigenetic
mechanism regulating pathophysiological process in glomer-
ular mesangial cells in the diabetic milieu.
Although it is possible that other factors in the diabetic
glomeruli, such as glomerular hypertension, paracrine or
endocrine factors, and oxidative stress, may affect HIF-1a
expression in these in vivo models, we showed the potential
contribution of high glucose ambience to HIF-1a induction
in cultured mesangial cells under normoxic conditions. In
particular, unlike hypoxia, high glucose upregulates HIF-1a
by increasing mRNA levels. Moreover, high glucose induces
through HIF-1a the genes encoding glucose transporter-1,
hexokinase II, CTGF, PAI-1, and vascular endothelial growth
factor, all of which are shown to exaggerate extracellular
matrix disposition in the glomeruli.15,16 The concentrations
of glucose to induce HIF-1a expression (above 11mmol)
seem relatively higher, yet they are within clinical range.
Therefore, such HIF-1-mediated signaling in mesangial cells
by high glucose might constitute the pathogenesis of diabetic
glomerulopathy. Similar to our results, a previous study47
showed that an overexpression of glucose transporter-1 in rat
mesangial cells causes upregulation of nuclear HIF-1a,
indicating an implication of HIF-1a expression in an
abnormal glucose metabolism in the mesangial cells. As the
cells in the glomeruli are perfused with arterial blood
containing a relatively higher level of oxygen, it might be
54 Kidney International (2010) 78, 48–59
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relevant that the mesangial cells use such a complex
regulatory mode of HIF-1-mediated signals without the aid
of hypoxia to respond to an altered cellular environment.
Gene regulation by high glucose is an important issue in
the molecular pathophysiology of metabolism. A transcrip-
tion factor ChREBP has been identified as a mediator of
glucose-responsive gene activation. The functional relevance
of ChREBP expressed in the kidney48 remains to be
determined. We observed that ChREBP-dependent activation
of HIF-1a gene promoter is critically involved in the glucose-
mediated upregulation of the HIF-1a mRNA in mesangial
cells. Moreover, loss-of-function experiments revealed that
ChREBP contributes to the glucose-dependent pathogenic
gene expression in mesangial cells, at least in part, through
HIF-1a. In addition, ChREBP is suggested to be involved in
upregulation of HIF-2a; thus, it might be possible that
ChREBP participates in broad aspects of HIF-mediated gene
regulations. Interestingly, in contrast to mesangial cells,
ChREBP was scarcely detected in the nucleus of renal tubular
epithelial cells. As HIF-1a induction by high glucose was
absent in the tubular epithelial cells, the nuclear ChREBP
level might be a determinant of the cell type-specific effect
NG NG HG
NG HG
PHD3
hMC
H
IF
-1
α
/β-
a
ct
in
mMC hRPTEC
*
*
*
Tubulin
Control
SenseAntisense
STZ
NG HG NG HG NG HG
NG+DP
1 2 3 4 5 6
7
4
5
6
1
0
2
3
21 3 4 5 6
– – 15 30 60 120CHX (min) – – 15 30 60 120CHX (min)
HIF-1α
α-Actinin
HIF-1α
α-Actinin
Figure 5 |High glucose enhances hypoxia-inducible factor-1a (HIF-1a) mRNA expression. (a, b) Mouse mesangial cells (mMC)
were incubated for 48 h in normal glucose (NG) medium (5.6mmol/l D-glucose) with 100mM 2,20-dipyrdyl (DP) (a) or in high glucose (HG)
medium (25mmol/l D-glucose) (b) and then cultured in the presence of cycloheximide (CHX; 50mmol/l) for indicated time periods (min).
The representative immunoblots for HIF-1a are shown. (c) The mMC were cultured in NG or HG medium for 48 h and then subjected
to immunoblot to assess the HIF prolyl hydroxylases 3 (PHD3) level. (d) Human mesangial cells (hMC) (n¼ 18), mMC (n¼ 8), and human
renal proximal tubular epithelial cells (hRPTEC, n¼ 12) were incubated for 48 h in NG or HG medium and HIF-1a mRNA levels were
determined by real-time PCR. The means±s.d. of the mRNA levels relative to cells in NG medium are presented. *Po0.05 in comparison to
the cells in NG medium. (e) In situ hybridization analysis of HIF-1a mRNA expression (dark purple signals) in the glomeruli of streptozotocin
(STZ)-induced diabetic or control mice. Bars¼ 25mm.
Kidney International (2010) 78, 48–59 55
T Isoe et al.: Activation of HIF-1 in the diabetic kidney o r ig ina l a r t i c l e
–350
E-box
–611
–611
E
–326 –233
E
E E
E
E
Human HIF1 gene
NG
HG
HG
NG
**
**
**
**
††
††
**
††
H
IF
-2
α
/β-
a
ct
in
PA
I-1
/β-
a
ct
in
CT
G
F/
β-a
ct
in
H
IF
-1
α
/β-
a
ct
in
HIF1 gene
–161/–314
Input IgG ChREBP
IP
2.0
1.5
1.0
0.5
0
HGNG HGNG HGNG
HG
3
2
1
0
6
4
2
0
NG
SiRNA
ChREBP
SiRNA
ChREBP
ChREBP
SiRNA
ChREBP
– –+ +
HGNG
NG HG NG HG
U2AF65
1 32 4
– –+ +
HGNG
– –+ +
5
4
3
2
1
0
HGNG HGNG HGNG
hMC mMC hRPTEC
hMC hRPTEC
*
*
*
*
Fold induction
Fold induction
6040200
0
6040200
ex1
luc
luc
luc pHIF-1α/–611
pHIF-1α/–326
PGL3-basic
pHIF-1α/–611 M1
pHIF-1α/–611 M2
PGL3-basic
pHIF-1α/–233
pHIF-1α/–326
pHIF-1α/–611
pHIF-1α/–233
luc
luc
luc
pHIF-1α/–611 M1
pHIF-1α/–611 M2
pHIF-1α/–611
E-box E-box
H
M
H
M
–280
–281
–211
a
b c
d e
f
i j
g h
Figure 6 |Carbohydrate response element binding protein (ChREBP) mediates hypoxia-inducible factor-1a (HIF-1a) mRNA induction
by high glucose. (a) Human (H) HIF-1a gene between 350 and 211 bp upstream from the transcriptional start site was aligned with
corresponding sequence of the mouse (M) HIF-1a gene. Conserved E-box-like elements (E-box) are shown. (b) A schematic representation
of the human HIF-1a promoter-driven firefly luciferase constructs. (c) Mouse mesangial cells (mMC) were transfected with human HIF-1a
promoter-driven firefly luciferase plasmids and cultured for 24 h in either normal glucose (NG, 5.6mmol/l, open bars) or high glucose
(HG, 25mmol/l, filled bars) medium. The cellular firefly luciferase activity was monitored and normalized by Renilla luciferase activity. The
means±s.d. of fold induction relative to the cells transfected with PGL3-basic vector in normal glucose medium are shown. *Po0.05 versus
the cells in NG medium. (d) A schematic representation of the reporter constructs carrying mutations in E-boxes. (e) mMC were transfected
with indicated mutant reporter plasmids. Luciferase assay was carried out and the results are shown as in c. (f) Human MC was cultured
in either NG or HG medium for 48 h, and chromatin immunoprecipitation assays using anti-ChREBP) antibody were then performed.
Rabbit polyclonal IgG (IgG) was applied as a control. PCR products amplifying indicated region of HIF-1a gene promoter by 35 cycles
was separated by electrophoresis. (g) mMC transfected with the small interfering RNA (siRNA) targeting ChREBP (ChREBP, þ ) were
incubated for 24 h in either NG or HG medium and the HIF-1a mRNA levels were determined by real-time PCR. An siRNA with scrambled
non-targeting sequence was used as a control (). The means±s.d. (n¼ 3) of the mRNA levels relative to cells in control siRNA-transfected
cells in NG medium are presented. **Po0.01; wwPo0.01. (h) Human mesangial cells (hMC) (n¼ 18), mMC (n¼ 8), and human renal proximal
tubular epithelial cells (hRPTEC, n¼ 12) were incubated for 48 h in NG or HG medium and HIF-2amRNA levels were determined by real-time
PCR. The means±s.d. of the mRNA levels relative to cells in NG medium are presented. **Po0.01 in comparison to the cells in NG medium.
(i) Nuclear extracts of hMC and hRPTEC cultured in NG or HG medium were subjected to immunoblot analyses for the amount of ChREBP
protein. The large subunit of U2 small nuclear ribonucleoprotein auxiliary factor (U2AF65) levels are shown as loading control. (j) mMC
transfected with the siRNA targeting ChREBP were incubated in NG or HG medium and connective tissue growth factor (CTGF) and
plasminogen activator inhibitor-1 (PAI-1) mRNA levels were determined by real-time PCR. The means±s.d. (n¼ 3) of the mRNA levels
relative to cells in control transfected cells in NG medium are presented. **Po0.01; wwPo0.01.
56 Kidney International (2010) 78, 48–59
or ig ina l a r t i c l e T Isoe et al.: Activation of HIF-1 in the diabetic kidney
of high glucose to induce HIF-1a. The downregulation of
HIF-1a and its target genes by either high glucose or diabetic
circumstances has been observed in dermal fibroblasts49 and
immortalized renal tubular cells,50 whereas the upregulation
of HIF-1a has been shown in cortical neurons by high
glucose.51 An examination of the ChREBP levels as well as the
levels of the heterodimerization partner, Mlx, in these cells
might help to understand the mechanism for such divergent
responses of cellular HIF-1a to high glucose. In this regard, a
recent report suggesting a downregulation of HIF-1b subunit
in pancreatic islet b cells by high glucose through ChREBP is
of interest.52
The dysregulated gene expression in the mesangial cells by
high glucose could be amended by siRNA-mediated knock-
down of HIF-1a. This could be of considerable importance in
developing a therapeutic approach to diabetic nephropathy.
HIF-1a is considered to have a core role in vascular biology;
therefore, the elucidation of the role of HIF-1a in glucose-
mediated signal transduction may widely define a novel
strategic milieu for the intervention of microvascular and macro-
vascular-cardiac complications in patient with diabetes.
MATERIALS AND METHODS
Reagents and antibodies
All chemicals were from Sigma-Aldrich (St Louis, MO), unless
specified. Mouse monoclonal or rabbit polyclonal anti-HIF-1a
antibody was obtained from BD bioscience (Franklin Lakes, NJ) or
Novus biologicals (Littleton, CO), respectively. Anti-ChREBP anti-
body was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-a-
actinin antibody was purchased from Sigma-Aldrich.
Cell culture
Human mesangial cells and renal tubular epithelial cells were
obtained from Lonza (Basel, Switzerland). The immortalized mouse
mesangial cells, SV40 MES 13, were from American Type Culture
Collection (Manassas, VA). Before each assay, the cells were serum
starved for 12 h in the media containing 0.2% bovine serum
albumin. Cellular responses to different glucose concentrations were
determined in the serum-free culture media for 48 h. The hypoxic
culture was as previously described.53
Immunoblotting
Whole-cell extract preparations and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis were as described.54 Primary
antibodies were incubated in Tris-buffered saline with 1% milk.
Secondary antibodies conjugated with horseradish peroxidase (GE
Healthcare, Buckinghamshire, UK) and the electrochemilumines-
cent detection system (GE Healthcare) were used for visualization.
For the semiquantitative analyses, the band densities were measured
using Multi gauge ver2.0 (Fujifilm, Tokyo, Japan).
Quantitative PCR analyses
Total RNAwas reverse-transcribed into cDNAwith oligo dT primers
using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA).
Quantitative PCR was performed using b-actin as internal standard
on the basis of TaqMan Gene Expression Assays (Applied Bio-
systems, Foster City, CA). The sequences of the oligonucleotide
probes are shown in Table 1.
Gene knockdown by siRNA
To knockdown HIF-1a or ChREBP, mouse mesangial cells were
transfected with the siRNA specifically targeting HIF-1a or ChREBP.
The sequences of the RNA are as follows: HIF-1a sense, 50-CCAUG
AUAUGUUUACUAAATT-30 and antisense, 50-UUUAGUAAACAUA
UCAUGGTT-30; ChREBP sense, 50-GGCCUCAAGUUGCUAUGCC
TT-30 and antisense, 50-GGCAUAGCAACUUGAGGCCTT-30. siRNA
with a non-targeting scrambled sequence was used as a control.
Transient transfection and luciferase assay
For the construction of HIF-1a promoter-driven firefly-luciferase
plasmids, fragments of the 50-flanking region of HIF-1a gene were
amplified by PCR and then cloned into pGL3-Basic vector
(Promega, Madison WI). Introduction of point mutations in
HIF-1a gene promoter was carried out by Gene Editor site-directed
mutagenesis system (Promega). The hypoxia-inducible luciferase
plasmid was described previously.37 The cells were transiently
transfected with luciferase plasmids and after 6 h the culture
medium was replaced with medium containing indicated
concentrations of glucose and incubated for 24 h. pRL-TK vector
(Promega) constitutively expressing Renilla reniformis luciferase
was used as a control for the normalization of transfection
efficiency.
Chromatin immunoprecipitation analysis
Fragments of the chromatin from human mesangial cells were
prepared as described previously,54 and then incubated with
rabbit polyclonal anti-ChREBP antibodies (Novus Biologicals)
or rabbit polyclonal immunoglobulin G and finally precipitated
by protein G-Sepharose. The precipitants were washed and eluted
and DNA was then purified using the PCR purification kit
(QIAGEN, Du¨sseldorf, Germany). PCR was performed using
primers flanking the ChRE within the HIF-1a gene promoter:
forward, 50-CTCTTTCCTCCGCCGCTAAAC-30 and reverse, 50-GG
TTCCTCGAGATCCAATGGC-30.
Table 1 | Sequences for the probes used in the real-time PCR
analysis
Species Gene Probe
Human HIF-1a 50-ATCACGACGGGCTGTGCTGAACACT-30
HIF-2a 50-CACAAGGTGTCAGGCATGGCAAGCC-30
CTGF 50-GGAAGAGAACATTAAGAAGGGCAAA-30
PAI-1 50-TCCTCCACAGCCTTTGTCATCTCAG-30
HKII 50-GATTGAGAGTGACTGCCTGGCCCTG-30
GLUT-1 50-CCCCCCAGAAGGTGATCGAGGAGTT-30
VEGF 50-TCATCACGAAGTGGTGAAGTTCATG-30
Adrenomedullin 50-ACTCTCTTAGCAGGGTCTGCGCTTC-30
b-actin 50-CCTTTGCCGATCCGCCGCCCGTCCA-30
Mouse HIF-1a 50-CACACAGAAATGGCCCAGTGAGAAA-30
HIF-2a 50-CAGAACTTGTGCACCAAGGGGCAGG-30
CTGF 50-TCGGAGTGTGCACTGCCAAAGATGG-30
PAI-1 50-TCCTCCACAGCCTTTGTCATCTCAG-30
HKII 50-CAGTGGAACCCAGCTGTTTGACCAC-30
GLUT-1 50-CAGCAGCAAGAAGGTGACGGGCCGC-30
VEGF 50-CTCCACCATGCCAAGTGGTCCCAGG-30
Adrenomedullin 50-CCTACAAGCCAGCAATCAGAGCGAA-30
b-actin 50-CTGTTACTGAGCTGCGTTTTACACC-30
Abbreviations: CTGF, connective tissue growth factor; GLUT-1, glucose transporter-1;
HIF, hypoxia-inducible factor; HKII, hexokinase II; PAI-1, plasminogen activator
inhibitor-1; VEGF, vascular endothelial growth factor.
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Animals
Male C57BL/6 mice, 8 weeks old, weighing 22–24 g were rendered
diabetic by the intraperitoneal injection of 100mg per kg body
weight streptozotocin in citrate buffer, pH 4.5, for 2 consecutive
days. The diabetic state was confirmed 5 days after final injection by
measurement of blood glucose level. All mice that were given
streptozotocin had a blood glucose concentration exceeding 400mg/
dl and were considered diabetic. Genetically diabetic male BKS.Cg-
þ Leprdb/þ Leprdb/Jcl (db/db) mice and their age-matched hetero-
zygous non-diabetic male littermates BKS.Cg-mþ /þ Leprdb/Jcl
(m/db) mice were obtained from CLEA Japan (Tokyo, Japan). All
animal experiments were conducted according to the institutional
guidelines for animal care and welfare.
Histological analyses of the kidney
The kidneys of the mice were fixed in 4% parafolmaldehyde,
dehydrated and embedded in paraffin. Then, 4 mm sections were
stained with periodic acid Schiff ’s reagent and hematoxylin.
Immunohistochemical analyses with monoclonal anti-HIF-1a anti-
body (Abcam, Cambridge, UK) were carried out as described.55 For
semiquantitative analyses, 25 glomeruli were subjected to counting
of HIF-1a-positive cells to determine the number of positive cells
per glomerulus and the ratio of positive cells to the total number of
the counted cells. Immunofluorescent analyses were performed by
incubation with polyclonal anti-HIF-1a antibody, monoclonal anti-
a-smooth muscle actinin antibody (Sigma-Aldrich), monoclonal
anti-Wilms’ tumor-1 antibody (Abcam), or monoclonal anti-CD34
antibody (Abcam) followed by fluorescence-conjugated secondary
antibodies. Staining with 40,6-diamidino-2-phenylindole was per-
formed to identify the nucleus.
Nonradioactive in situ hybridization procedures
cDNA encoding 1–330 amino acids of HIF-1a protein was amplified
by PCR and cloned into pCDNA3 vector (Invitrogen) and used as a
template for synthesis of digoxigenin-labeled antisense or sense
probes. Sections were hybridized with the riboprobes and revelation
was performed as described previously.56
Statistical analysis
All data are presented as means±s.d. from the experiments with
repetitions as indicated. Comparisons between two groups were
analyzed using t-test. One-factor analysis of variance and two-factor
factorial analysis of variance followed by the Bonferroni/Dunn test
were carried out to determine significant differences in multiple
comparisons. The P-values of o0.05 were considered to be
significant.
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